Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
Summary from New York Times
How 4 outlets are covering it
-
NBC NewsPersonalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
Read on NBC News -
CNBCDoctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
Read on CNBC -
New York TimesCancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
Read on New York Times -
Ars TechnicaModerna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
Read on Ars Technica -
CNBCModerna shares plunge after leak of partial cancer vaccine data
Moderna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.
Read on CNBC
